加载中
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
前收盘价
US$166
−US$2.35 · -1.40%
盘后
US$166
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
日内区间
当前US$166
52周区间
当前US$166
盘中时间采用ET。市场数据可能有所延迟。
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
日内区间
当前US$166
52周区间
当前US$166
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 6.38亿 USD | 3.86亿 USD | 2.71亿 USD | 5003.7万 USD | — |
| 销货成本 | 4747.8万 USD | 3330.3万 USD | 2606.5万 USD | 519.8万 USD | — |
| 毛利 | 5.91亿 USD | 3.52亿 USD | 2.45亿 USD | 4483.9万 USD | — |
| 研究与开发 | 1.83亿 USD | 1.87亿 USD | 9794.4万 USD | 5794.7万 USD | 5806.1万 USD |
| 销售、一般及管理费用 | 5.71亿 USD | 4.11亿 USD | 3.23亿 USD | 1.59亿 USD | 6664.6万 USD |
| 营业费用 | 7.6亿 USD | 6.33亿 USD | 4.76亿 USD | 2.25亿 USD | 1.25亿 USD |
| 利息收入 | 937.1万 USD | — | — | — | — |
| 利息支出 | 655.7万 USD | 656.9万 USD | 645.3万 USD | 733.5万 USD | 569.6万 USD |
| 折旧和摊销 | 906.4万 USD | 795.8万 USD | 683.4万 USD | 440.2万 USD | 7.6万 USD |
| 营业利润 | −1.69亿 USD | −2.81亿 USD | −2.32亿 USD | −1.8亿 USD | −1.25亿 USD |
| 净利润 | −1.83亿 USD | −2.87亿 USD | −2.39亿 USD | −1.87亿 USD | −1.3亿 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2.76亿0.01%2.3万亿 USD0.03%US$381.57-0.10%
Vanguard Morningstar Small-Cap ETFVB2亿0.11%1853亿 USD0.03%US$288.16-0.46%
Vanguard Morningstar Small-Cap Growth ETFVBK1.15亿0.25%447亿 USD0.05%US$340.88-1.12%
Vanguard Extended Market ETFVXF9971.92万0.10%954亿 USD0.05%US$233.52-0.63%
First Trust NYSE Arca Biotechnology Index FundFBT6519.2万2.25%28.91亿 USD0.55%US$263.9-0.57%
iShares Biotechnology ETFIBB5757万0.53%108.2亿 USD0.44%US$204.26-1.08%
iShares Russell Mid-Cap Growth ETFIWP4092.5万0.20%200.95亿 USD0.23%US$140.99-1.47%
Schwab U.S. Small-Cap ETFSCHA3958.95万0.18%218.24亿 USD0.03%US$32.66-0.40%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFFirst Trust NYSE Arca Biotechnology Index FundFBTiShares Biotechnology ETFIBBiShares Russell Mid-Cap Growth ETFIWPSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
